Does neoadjuvant therapy improve survival in pancreatic adenocarcinoma?

Pancreatic ductal adenocarcinoma(PDAC)is an aggressive malignancy with early recurrence.Currently,the 5-year survival of pancreatic cancer is 10%,with less than 40%survival even in localized disease(1).The early distant recurrence rate,following surgical resection,is likely driven by the presence of occult micro-metastasis at diagnosis,warranting the use of systemic therapy.